Rocket Pharmaceuticals Announces Participation at Upcoming Conferences
Nov 1, 2018
|
NEW YORK--(BUSINESS WIRE)--Nov. 1, 2018--
Rocket
Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”), a leading
U.S.-based multi-platform gene therapy company, announces participation
at the following upcoming industry conferences:
-
Evercore ISI HealthConX Conference
-
Gaurav Shah, M.D., Chief Executive Officer and President, will
participate in a fireside chat on November 28, 2018, at 1:15 p.m.
Eastern Time in Boston, MA
-
Barclays Gene Editing & Gene Therapy Summit
-
Dr. Shah will present on November 29, 2018, at 11:15 a.m. Eastern
Time in New York, NY
-
American Society of Hematology 2018 Annual Meeting
-
Dr. Juan Bueren, Head of the Hematopoietic Innovative Therapies
Division at CIEMAT in Spain and program principal investigator of
the Phase 1/2 trial of RP-L102, will present the abstract
“Advances in the Gene Therapy of Patients with Fanconi Anemia” in
an oral session on December 3, 2018, at 6:30 p.m. Pacific Time in
San Diego, CA. The presentation will include long-term follow up
data from the first four patients treated, as presented at the
2018 Annual Congress of the European Society of Gene and Cell
Therapy in October.
A live audio webcast of the Evercore ISI presentation will be available
on the Investors section of the company’s website, www.rocketpharma.com.
A replay of the presentation will be archived on the Rocket website
following the conference.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is an emerging,
clinical-stage biotechnology company focused on developing
first-in-class gene therapy treatment options for rare, devastating
diseases. Rocket’s multi-platform development approach applies the
well-established lentiviral vector (LVV) and adeno-associated viral
vector (AAV) gene therapy platforms. Rocket's lead clinical program is a
LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a
difficult to treat genetic disease that leads to bone marrow failure and
potentially cancer. Preclinical studies of additional bone
marrow-derived disorders are ongoing and target Pyruvate Kinase
Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile
Malignant Osteopetrosis (IMO). Rocket is also developing an AAV-based
gene therapy program for an undisclosed rare pediatric disease. For more
information about Rocket, please visit www.rocketpharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181101005623/en/
Source: Rocket Pharmaceuticals, Inc.
Claudine Prowse, Ph.D.
SVP, Corporate Strategy and IRO
Rocket
Pharma, Inc.
The Empire State Building, Suite 7530
New York,
NY 10118
cp@rocketpharma.com
www.rocketpharma.com
investors@rocketpharma.com